The study also determined that CFLAR likely inhibited the MAP3K5/ASK-1/JNK1 pathway and it should be noted that an ASK-1 inhibitor is already being tested in a clinical trial for the treatment of NASH [66]. Here, MAP3K5 is linked to metabolic dysfunction-associated steatohepatitis.